HLA-B Antigens

"HLA-B Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.

Descriptor ID	D015235
MeSH Number(s)	D12.776.395.550.489.500 D12.776.543.550.439.500 D23.050.301.500.100.500 D23.050.301.500.450.380 D23.050.705.552.100.500 D23.050.705.552.450.380
Concept/Terms	HLA-B Antigens HLA-B Antigens HLA B Antigens HLA-B Antigens, HLA-B Antigens, HLA B

Below are MeSH descriptors whose meaning is more general than "HLA-B Antigens".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Glycoproteins [D12.776.395]
Membrane Glycoproteins [D12.776.395.550]
Histocompatibility Antigens Class I [D12.776.395.550.489]
HLA-B Antigens [D12.776.395.550.489.500]
Membrane Proteins [D12.776.543]
Membrane Glycoproteins [D12.776.543.550]
Histocompatibility Antigens Class I [D12.776.543.550.439]
HLA-B Antigens [D12.776.543.550.439.500]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Histocompatibility Antigens [D23.050.301.500]
Histocompatibility Antigens Class I [D23.050.301.500.100]
HLA-B Antigens [D23.050.301.500.100.500]
HLA Antigens [D23.050.301.500.450]
HLA-B Antigens [D23.050.301.500.450.380]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
Histocompatibility Antigens Class I [D23.050.705.552.100]
HLA-B Antigens [D23.050.705.552.100.500]
HLA Antigens [D23.050.705.552.450]
HLA-B Antigens [D23.050.705.552.450.380]

Below are MeSH descriptors whose meaning is related to "HLA-B Antigens".

Below are MeSH descriptors whose meaning is more specific than "HLA-B Antigens".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "HLA-B Antigens" by people in this website by year, and whether "HLA-B Antigens" was a major or minor topic of these publications.

Bar chart showing 9 publications over 8 distinct years, with a maximum of 2 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
2004	0	1	1
2006	1	0	1
2008	1	0	1
2010	0	2	2
2014	1	0	1
2020	1	0	1
2021	0	1	1

Below are the most recent publications written about "HLA-B Antigens" by people in Profiles.

Schoenberg E, Mehregan D, Colombe B, Hazan E, Dasgeb B. The potential role of HLA typing to risk stratify melanoma patients on immunotherapy with associated SJS: pitfalls and opportunities. Int J Dermatol. 2022 09; 61(9):e335-e337.

View in: PubMed
Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, Ta Michael Lee M, Llerena A, Whirl-Carrillo M, Klein TE, Phillips EJ, Mintzer S, Gaedigk A, Caudle KE, Callaghan JT. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021 02; 109(2):302-309.

View in: PubMed
Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov; 96(5):542-8.

View in: PubMed
Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M, Gajewski J, Hale GA, Horan J, Battiwalla M, Marino SR, Setterholm M, Ringden O, Hurley C, Flomenberg N, Anasetti C, Fernandez-Vina M, Lee SJ. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):885-92.

View in: PubMed
Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010 Mar-Apr; 11(2):69-79.

View in: PubMed
Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS. 2008 Aug 20; 22(13):1673-5.

View in: PubMed
Navarro V, Herrine S, Katopes C, Colombe B, Spain CV. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. Liver Transpl. 2006 Apr; 12(4):652-8.

View in: PubMed
Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004 Oct 01; 104(7):1923-30.

View in: PubMed
Gilman A, Auger JJ, Terry L, Flomenberg N, Baxter-Lowe LA. HLA-B14 subtypes and their influence on allorecognition. Tissue Antigens. 1996 Mar; 47(3):253-6.

View in: PubMed
Altman EM, Centeno LV, Mahal M, Bielory L. AIDS-associated Reiter's syndrome. Ann Allergy. 1994 Apr; 72(4):307-16.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement